Is Haemonetics Corp. overvalued or undervalued?

As of 25 August 2025, the valuation grade for Haemonetics Corp. has moved from attractive to very attractive, indicating a stronger position in the market. The company appears to be undervalued, especially when considering its P/E ratio of 22, which is significantly higher than the peer average of 16.35 for companies like Masimo Corp. and Bio-Rad Laboratories, Inc. Additionally, Haemonetics has an EV/EBITDA ratio of 13.04, which is lower than the industry average, suggesting potential for growth.
In comparison to its peers, Haemonetics Corp. maintains a favorable ROE of 18.58% and ROCE of 12.30%, both of which highlight its efficiency in generating returns relative to its equity and capital employed. Despite this positive valuation outlook, the stock has underperformed against the S&P 500, with a year-to-date return of -34.49% compared to the index's 12.22%, indicating that while the company may be fundamentally strong, market sentiment has not aligned with its valuation metrics.